Chargement de l’entreprise
Just reported
From ELI Lilly's results release of 29 octobre 2026; its quarterly report has since been filed.
Actual
24,4B $US
+39 % y/y
+6,2 % q/q
Guided
—
No guide given
Actual
7,22 $US
+16 % y/y
-9,1 % q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Les parts du chiffre d'affaires sont des estimations pour year ended December 31, 2025, pas des chiffres tirés d'un document officiel.
Mounjaro
A medicine used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Zepbound
A medicine for adults with obesity, or overweight with a weight-related health condition. It is also approved for certain adults with obesity and moderate to severe sleep apnea.
Foundayo (orforglipron)
An oral medicine approved in the United States for obesity. Lilly has also submitted it for review as a treatment for type 2 diabetes.
Verzenio
A medicine used alone or with hormone treatment for certain adults with hormone receptor-positive breast cancer.
Jardiance
A medicine used for type 2 diabetes and to reduce certain risks related to heart failure and chronic kidney disease. Lilly markets it in collaboration with Boehringer Ingelheim.
Trulicity
A medicine for type 2 diabetes in adults and some children, and to reduce the risk of certain heart problems in some adults with type 2 diabetes.
Lilly researches, develops, manufactures, and sells human medicines in the United States and around the world. Its medicines treat conditions including type 2 diabetes, obesity, cancer, inflammatory diseases, migraine, and Alzheimer's disease. It also works with other companies on research, development, and marketing of some medicines.
Construit à partir des documents déposés par ELI Lilly & Co auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
Lilly discovers, makes, and sells prescription medicines for diseases including diabetes, obesity, cancer, and inflammatory conditions.
Prévision de l’entreprise : chiffre d’affaires de de 91B $US à 92B $US pour Exercice 2026 — en hausse de 40,4 % sur un an
The themes ELI Lilly is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 41 de l’historique des notes de ELI Lilly & Co. Les 39 autres remontent jusqu’à octobre 2016.
